Galmed (GLMD) adjourns AGM; reconvenes Oct 29, 2025 in Israel

Galmed Pharmaceuticals reported that its Annual General Meeting of Shareholders was convened but adjourned for one day due to lack of quorum.

Accepted by SEC EDGAR 10/28/2025 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Galmed Pharmaceuticals reported that its Annual General Meeting of Shareholders was convened but adjourned for one day due to lack of quorum. The meeting will reconvene on October 29, 2025 at 4:00 p.m. Israel time at Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.

This report is incorporated by reference into the company’s Registration Statements on Form S-8 (Nos. 333-206292, 333-227441, 333-284163, 333-290399) and Form F-3 (Nos. 333-272722, 333-283241).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Galmed (GLMD) announce in this Form 6-K?

The company adjourned its Annual General Meeting due to lack of quorum and will reconvene on October 29, 2025 at 4:00 p.m. Israel time in Ramat Gan.

Why was Galmed's AGM adjourned?

It was adjourned for one day due to a lack of quorum.

When and where will the Galmed AGM reconvene?

On October 29, 2025 at 4:00 p.m. Israel time at Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.

Which registration statements does this 6-K incorporate by reference?

It is incorporated into Form S-8 Nos. 333-206292, 333-227441, 333-284163, 333-290399 and Form F-3 Nos. 333-272722, 333-283241.

Who signed the report for Galmed Pharmaceuticals?

It was signed by Allen Baharaff, President and Chief Executive Officer.

What is the form type of this filing?

This is a Form 6-K report of a foreign private issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of October 2025

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On October 28, 2025, Galmed Pharmaceuticals Ltd. (the “Company”) convened an Annual General Meeting of Shareholders (the “Meeting”), however, the Meeting was adjourned for one day to the same time and place due to lack of quorum. Accordingly, the Meeting will be reconvened on Wednesday, October 29, 2025 at 4:00 p.m., Israel time at the at the offices of Meitar | Law Offices, legal counsel to the Company at 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163, and 333-290399) and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: October 28, 2025	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer